08:13 AM EST, 02/17/2026 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Tuesday that the Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell's Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer.

The ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration (FDA), reflecting the significant unmet medical need in metastatic breast cancer, a statement noted.

"This marks the fifth consecutive DSMB review supporting the continued conduct of BriaCell's pivotal Phase 3 Bria-ABC study," said Dr. William Williams, chief executive officer. "We are encouraged by the DSMB's ongoing confirmation of the safety profile of the Bria-IMT regimen and remain focused on advancing this program for patients with limited treatment options."